ESR1 and breast cancer: In premenopausal women, oestrogen receptor positive (ER+) disease constitutes over 80% of breast cancers.1 The vast majority of these patients will receive endocrine therapy, often by ovarian ablation, although ER status is an imperfect predictor of response to this therapy.